Time Limit Dooms Nexium Antitrust Claims, AstraZeneca Says

Law360, Los Angeles (October 16, 2013, 9:00 PM ET) -- AstraZeneca PLC and Ranbaxy Inc. filed for partial summary judgment Tuesday in multidistrict litigation alleging the companies violated antitrust laws by agreeing to delay entry of a generic version of AstraZeneca’s heartburn drug Nexium, saying a four-year statute of limitations on some claims has run out.

AstraZeneca and generics manufacturer Ranbaxy say Ranbaxy’s alleged exclusion from the market due to a settlement between the two companies over patent infringement happened more than four years before the suit was filed and that the continuing-violation exception to the...
To view the full article, register now.